Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:15 2024-04-18 am EDT 		5-day change 1st Jan Change
45.4 HKD -2.89% Intraday chart for Akeso, Inc. -6.87% -2.16%
Mar. 22 Akeso to Raise Over HK$1 Billion Via Share Sale MT
Mar. 19 Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Akeso, Inc.

Akeso to Raise Over HK$1 Billion Via Share Sale MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5% MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3% MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer CI
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023 CI
Akeso Publishes Results from Three Investigator-Initiated Trials CI
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate its Innovation Globalization Strategy CI
Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival for First-Line Treatment of Recurrent/Metastatic Cervical Cancer CI
Akeso's Phase 3 Trial for Cervical Cancer Attains Progression-Free Survival MT
Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer CI
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) CI
Akeso's Clinical Trial for Gastroesophageal Cancer Treatment Achieves Primary Outcomes MT
Akeso, Inc. Announces A Phase III Trial of Cadonilimab in Combination with Chemotherapy as First Line Treatment for GASTRIC or Gastesophageal Junction Adenocarcinoma (GC/GEJC) Reaches Primary Endpoint of Overall Survival CI
Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody CI
Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study CI
Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201) CI

Chart Akeso, Inc.

Chart Akeso, Inc.
More charts

Company Profile

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Sector
Biotechnology & Medical Research
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
43.21 CNY
Average target price
55.21 CNY
Spread / Average Target
+27.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKESO, INC. Stock Akeso, Inc.
-2.16% 5.17B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.84B
ARGENX SE Stock argenx SE
-0.76% 21.48B
BIONTECH SE Stock BioNTech SE
-18.14% 20.82B
GENMAB A/S Stock Genmab A/S
-7.29% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. News Akeso, Inc.
  5. UBS Adjusts Akeso’s Price Target to HK$26.68 From HK$29.60, Keeps at Buy